FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to the use of at least one gastric release-controlling polymer with mucoadhesive properties to produce an oral delivery system of 2-ethyl-6-methyl-3-hydroxypyridine succinate in the form of a gastroretentive tablet. For this, at least one polymer is selected from polyalkylene oxide. Group of inventions also relates to a gastroretentive tablet containing an oral delivery system and 2-ethyl-6-methyl-3-hydroxypyridine succinate, and also relates to a method for increasing bioavailability of 2-ethyl-6-methyl-3-hydroxypyridine succinate.
EFFECT: invention provides higher bioavailability of the active substance, as well as reduced frequency of the drug administration.
14 cl, 8 dwg, 8 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MACOZINONE-BASED PHARMACEUTICAL COMPOSITION FOR TREATMENT OF TUBERCULOSIS INCLUDING MULTI- AND EXTENSIVELY DRUG-RESISTANT FORMS THEREOF | 2020 |
|
RU2751163C1 |
| MODIFIED RELEASE 6-METHYL-2-ETHYL-HYDROXYPYRIDINE SUCCINATE DOSAGE FORM | 2008 |
|
RU2411035C2 |
| PHARMACEUTICAL COMPOSITION WITH 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE SUCCINATE FOR ORAL ADMINISTRATION AND METHOD FOR PREPARING IT | 2010 |
|
RU2444359C1 |
| SOLID ORAL DOSAGE FORM PROLONGED RELEASING ACTIVE PHARMACEUTICAL SUBSTATION (APS) IN UPPER PART OF STOMACH | 2021 |
|
RU2786063C2 |
| METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION HAVING NEUROPROTECTIVE ACTIVITY IN CHRONIC CEREBRAL ISCHEMIA | 2023 |
|
RU2816359C1 |
| GASTRO-RETENTIVE ORAL PHARMACEUTICAL COMPOSITIONS | 2014 |
|
RU2666996C1 |
| PHARMACEUTICAL COMPOSITION IN THE FORM OF A COATED TABLET | 2022 |
|
RU2786073C1 |
| CONTROLLED-RELEASE PHARMACEUTICAL PROXODOLOL COMPOSITION | 2007 |
|
RU2356532C2 |
| PHARMACEUTICAL COMPOSITION OF METFORMIN WITH PROLONGED RELEASE AND METHOD OF ITS OBTAINING | 2006 |
|
RU2433821C2 |
| CONTROLLED-RELEASE FORMULATION | 2006 |
|
RU2385712C2 |
